What it's for (Indications)
- Ezetimibe + simvastatin is indicated as an adjunct to diet for the reduction of elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult and adolescent patients aged 10 years and older with primary hypercholesterolemia (heterozygous familial and nonfamilial).
- It is also indicated for the reduction of elevated TC and LDL-C in adult patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.
- g.
- , LDL apheresis) or if such treatments are unavailable.
- Furthermore, this combination medication is used for the reduction of elevated sitosterol and campesterol levels in patients with homozygous sitosterolemia (phytosterolemia).
- Its comprehensive action aims to improve overall lipid profiles, thereby reducing the risk of cardiovascular events in susceptible populations.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of ezetimibe + simvastatin is one tablet orally once daily in the evening, with or without food. Dosage strengths typically range from ezetimibe 10 mg combined with simvastatin 10 mg, 20 mg, 40 mg, or in some cases, 80 mg. The initial dose should be individualized based on the patient's current lipid levels, cardiovascular risk factors, and prior response to lipid-lowering therapy. For most patients requiring a moderate to high reduction in LDL-C, a common starting dose might be ezetimibe 10 mg/simvastatin 20 mg or 10 mg/40 mg. The 80 mg dose of simvastatin is generally not recommended for new patients, or for patients currently taking lower doses who need additional LDL-C reduction, due to an increased risk of myopathy, including rhabdomyolysis. If a patient is currently tolerating ezetimibe 10 mg/simvastatin 80 mg and requires continued therapy, careful monitoring for adverse effects is essential. Dosage adjustments should be made at intervals of 4 weeks or more, based on lipid assessments and clinical response. Concomitant use with other medications should be carefully considered due to potential drug interactions affecting simvastatin metabolism. |
Safety & Warnings
Common Side Effects
- Common side effects reported with ezetimibe + simvastatin include headache, abdominal pain, diarrhea, constipation, flatulence, nausea, fatigue, myalgia (muscle pain), and arthralgia (joint pain).
- More serious, though less frequent, adverse reactions warrant immediate medical attention.
- These include myopathy, characterized by unexplained muscle pain, tenderness, or weakness, and its severe form, rhabdomyolysis, which can lead to kidney failure.
- Patients may also experience elevated serum transaminases (liver enzymes), indicative of liver dysfunction or hepatitis, which necessitates monitoring of liver function tests.
- Other potential serious adverse effects include pancreatitis, hypersensitivity reactions such as rash, urticaria, and angioedema.
- Cases of increased HbA1c and fasting blood glucose levels have been observed with statin therapy, indicating a potential risk for new-onset diabetes mellitus or worsening of existing diabetes.
- Patients should be advised to report any unusual muscle symptoms, dark urine, or persistent gastrointestinal discomfort to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: While ezetimibe + simvastatin does not carry a formal FDA Black Box Warning, it is imperative to highlight the very serious potential for myopathy and rhabdomyolysis, which can lead to acute renal failure. This risk is a critical safety consideration for all patients receiving this combination therapy. The incidence of myopathy is significantly increased with higher doses of the simvastatin component, particularly the 80 mg daily dose, which is generally restricted to patients who have tolerated it for an extended period without muscle-related adverse events and who require additional intensive lipid lowering. For new patients or those escalating therapy, the 80 mg dose is not recommended due to a disproportionate increase in myopathy risk. Furthermore, the co-administration of simvastatin with drugs that are potent inhibitors of cytochrome P450 3A4 (CYP3A4) — such as certain antifungals (e.g., itraconazole, ketoconazole), macrolide antibiotics (e.g., erythromycin, clarithromycin), HIV protease inhibitors, and nefazodone — substantially elevates simvastatin plasma concentrations and consequently escalates the risk of myopathy and rhabdomyolysis. Healthcare providers must carefully evaluate all concomitant medications and patient risk factors, including hypothyroidism and renal impairment, before prescribing and throughout the course of treatment. Patients must be counselled to report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever, to their physician immediately to allow for prompt evaluation and discontinuation if indicated.
- Ezetimibe + simvastatin carries several important warnings due to the inherent risks associated with its components.
- A primary concern is the risk of myopathy, which can progress to rhabdomyolysis, a potentially life-threatening condition involving severe muscle breakdown and renal failure.
- This risk is dose-related, particularly at the highest simvastatin dose (80 mg), and is significantly increased with concomitant use of certain medications that inhibit the cytochrome P450 3A4 (CYP3A4) enzyme, which metabolizes simvastatin.
- These include strong CYP3A4 inhibitors, cyclosporine, danazol, and gemfibrozil, among others.
- Patients should be counseled to immediately report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever.
- Liver enzyme elevations (transaminases) have been observed; therefore, liver function tests should be performed before initiating therapy and periodically thereafter, or when clinically indicated.
- Persistent elevations warrant dose reduction or discontinuation.
- Statins, including simvastatin, have been reported to increase HbA1c and fasting glucose levels, potentially leading to new-onset diabetes.
- Furthermore, ezetimibe + simvastatin is contraindicated in pregnancy and lactation due to the potential for fetal harm; women of childbearing potential should use effective contraception.
- Hypothyroidism should be adequately treated prior to initiating therapy, as uncontrolled hypothyroidism can potentiate myopathy.
How it Works (Mechanism of Action)
The therapeutic efficacy of ezetimibe + simvastatin stems from the synergistic action of its two distinct lipid-modifying components. Ezetimibe, a selective cholesterol absorption inhibitor, acts at the brush border of the small intestine to block the absorption of dietary and biliary cholesterol without affecting the absorption of fat-soluble vitamins or triglycerides. It specifically targets the Niemann-Pick C1-Like 1 (NPC1L1) protein, a critical mediator of intestinal cholesterol absorption. By reducing the delivery of intestinal cholesterol to the liver, ezetimibe prompts the liver to increase its uptake of LDL-C from the bloodstream. Simvastatin, a member of the HMG-CoA reductase inhibitor class (statins), acts intracellularly in the liver. It is a prodrug that is hydrolyzed to its active β-hydroxyacid form. This active metabolite competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme responsible for the rate-limiting step in endogenous cholesterol biosynthesis. The inhibition of hepatic cholesterol synthesis leads to a compensatory upregulation of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, which in turn enhances the clearance of circulating LDL-C from the plasma. The combined action of reducing both exogenous (ezetimibe) and endogenous (simvastatin) cholesterol sources provides a more potent lipid-lowering effect than either agent alone.